MRG003 and Toripalimab before surgery for head and neck cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests a combination of two drugs (MRG003 and Toripalimab) given before surgery to shrink head and neck cancer tumors. It's for people with a specific type of cancer that hasn't been treated before and is PD-L1 positive.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a PD-L1-positive head and neck cancer (a score of 1 or higher).
- Your cancer must be in a specific area (mouth, voice box, throat, or back of throat) and can be removed with surgery.
- You cannot have had any previous cancer treatment like chemotherapy, radiation, or immunotherapy.
- You must be between 18 and 70 years old.
- You must be in good enough health to be active and do light work (ECOG 0 or 1).
- Your kidney and liver function must be within a certain healthy range.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests toripalimab (an immunotherapy) given before surgery for untreated head and neck squamous cell carcinoma, either alone or with chemotherapy. The goal is to shrink or control the cancer earlier and see if it improves outcomes for people who plan curative surgery.
This trial tests a combination of two drugs—an immunotherapy (PD-1 inhibitor) and a targeted therapy (cetuximab)—given before surgery to shrink advanced head and neck cancers. The goal is to see if this approach can lower the risk of the cancer coming back.
This trial tests a combination of two targeted drugs for advanced head and neck cancer that has not responded to standard treatments. It specifically includes patients whose tumors have a change in the CDKN2A gene.
This trial tests a combination of three drugs (becotatug vedotin, pucotenlimab, and cisplatin) given before surgery for head and neck cancer that has not spread far. The goal is to see if this treatment shrinks tumors and improves outcomes for patients with stage 3 or 4A disease.
This trial tests a combination of two drugs (Adebrelimab, an immunotherapy that helps your immune system attack cancer cells, and Dalpiciclib, a targeted therapy that stops cancer cells from dividing) given before surgery for a type of head and neck cancer. It is looking at whether this treatment can improve outcomes for people with HPV-negative, locally advanced head and neck squamous cell carcinoma that can be surgically removed.
This trial tests a combination of three drugs (tirelizumab, carboplatin, and a special form of paclitaxel) given before surgery to treat advanced head and neck cancer. The goal is to see if this treatment can shrink the tumor and improve outcomes.
Hear when a new Head and Neck Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.